Who is sponsoring NCT04649931?

NCT04649931 is sponsored by B. Braun Melsungen AG.

What drugs are being tested in NCT04649931?

Interventions in NCT04649931: Ion Mobility Spectrometry (IMS).

What condition does NCT04649931 study?

NCT04649931 studies SARS (Severe Acute Respiratory Syndrome), Covid19.

Is NCT04649931 still recruiting?

NCT04649931 is currently completed. Last updated 3 May 2021.

Last reviewed 2021-05-03 · How we verify

NCT04649931

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease)

Completed Last updated 3 May 2021

What this trial tests

trial testing Ion Mobility Spectrometry (IMS) in SARS (Severe Acute Respiratory Syndrome) in 450 participants. Completed in 25 April 2021.

Timeline

14 December 2020

Primary endpoint
25 April 2021

25 April 2021

Quick facts

Lead sponsor	B. Braun Melsungen AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	450
Start date	14 December 2020
Primary completion	25 April 2021
Estimated completion	25 April 2021
Sites	1 location across Germany

Drugs / interventions tested

Ion Mobility Spectrometry (IMS)

Conditions studied

SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →
Covid19 — all drugs for Covid19 →

Sponsor

B. Braun Melsungen AG — full company profile →

Who can join

18 and older, any sex, with SARS (Severe Acute Respiratory Syndrome) or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Breath gas analysis is the evaluation of exhaled breath. It aims to evaluate the volatile organic compounds (VOCs) in exhaled breath. In this feasibility study it is intended to find specific peaks/pattern in exhaled breath indicating an infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ion Mobility Spectrometry (IMS)

Trials testing the same drug.

NCT04556318 — Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19) · completed

Other B. Braun Melsungen AG trials

Trials by the same sponsor.

NCT05124821 — Evaluation of Performance Over Dwell Time and Safety of the Central-venous Catheters Certofix® Paed · completed
NCT04470934 — SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF) · active not recruiting
NCT04556318 — Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19) · completed
NCT03809715 — Coroflex ISAR NEO "All Comers" Post Market Clinical Follow-up (PMCF) · completed
NCT03282955 — The HOME Study (HPN With OMEGA-3) · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04649931 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by B. Braun Melsungen AG
Last refreshed: 3 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04649931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing